ACROBiosystems stands as a pivotal force within the pharmaceutical and biotechnology sectors, dedicated to providing innovative tools and solutions that span from initial discovery to clinical application. Their range of life science tools caters to researchers at every stage, offering recombinant proteins, antibodies, assay kits, GMP-grade reagents, and custom services. By staying abreast of evolving regulatory landscapes, ACROBiosystems equips scientists and engineers with the resources needed to streamline and expedite the development of groundbreaking, cost-effective medicines. Biomarkers play a crucial role in unlocking the potential of biological drugs, offering valuable insights into mechanisms of action, guiding clinical trial designs, and optimizing treatment approaches. These biomarkers are instrumental across all stages of drug development, from early discovery to clinical trials, enabling precise dosing and efficacy assessments.
In the realm of autoimmune diseases, a significant amount of research is dedicated to developing biological drugs that target well-defined disease mechanisms and specific molecular pathways. Conditions such as Crohn’s disease, plaque psoriasis, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis are at the forefront of drug development efforts, with over 1,100 potential candidates currently in various pipelines. The primary targets for these therapies revolve around the TNF/IL-23/IL-17 axis, with key biomarkers and cytokines including TNF-α, IL-23p19, IL-17A, IL-12/23p40, IL-17F, and TL1A. Noteworthy targeted drugs already in circulation include adalimumab, ustekinumab, secukinumab, guselkumab, tildrakizumab, and risankizumab. Delving into the intricate pathogenesis of IL-17-associated diseases and the diverse therapeutic targets available, the field of biological drugs in autoimmune diseases continues to evolve and expand. For further insights on this topic, refer to the detailed whitepaper available at news-medical.net.
Tags: biotechnology
Read more from news-medical.net